| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.
|
Cell
|
2007
|
3.40
|
|
2
|
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.
|
J Clin Invest
|
2007
|
2.22
|
|
3
|
The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis.
|
Mol Biol Cell
|
2005
|
1.85
|
|
4
|
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
|
Cancer Res
|
2005
|
1.75
|
|
5
|
Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.
|
Breast Cancer Res
|
2003
|
1.23
|
|
6
|
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.14
|
|
7
|
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
|
J Clin Oncol
|
2009
|
1.08
|
|
8
|
WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors.
|
Mol Endocrinol
|
2006
|
1.07
|
|
9
|
Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.
|
Endocr Relat Cancer
|
2011
|
0.95
|
|
10
|
New insights on the role of hormonal therapy in ovarian cancer.
|
Steroids
|
2013
|
0.94
|
|
11
|
A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
|
Clin Breast Cancer
|
2008
|
0.92
|
|
12
|
Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells.
|
J Proteome Res
|
2005
|
0.84
|
|
13
|
Integration of genomic and non-genomic steroid receptor actions.
|
Steroids
|
2013
|
0.75
|